Have a feature idea you'd love to see implemented?
Let us know!
TRML Tourmaline Bio Inc
Price (delayed)
$22.72
Market cap
$582.6M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.4
Enterprise value
$547.66M
talaris therapeutics is a late-clinical stage biotechnology company based in boston, ma and louisville, ky. talaris is developing transformative cell therapies with the potential to eliminate the burden of chronic
Highlights
TRML's EPS has surged by 99% year-on-year and by 92% since the previous quarter
The company's debt has shrunk by 54% YoY and by 13% QoQ
TRML's equity has soared by 125% year-on-year but it is down by 5% since the previous quarter
The quick ratio has soared by 114% YoY but it has contracted by 15% from the previous quarter
Tourmaline Bio's net income has decreased by 43% QoQ
Key stats
What are the main financial stats of TRML
Market
Valuations
Earnings
Shares outstanding
25.64M
Market cap
$582.6M
Enterprise value
$547.66M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.81
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$48.85M
EBITDA
-$49.69M
Free cash flow
-$44.87M
Per share
Balance sheet
Liquidity
EPS
-$0.4
Free cash flow per share
-$1.74
Book value per share
$12.52
Revenue per share
$0
TBVPS
$12.75
Total assets
$328.45M
Total liabilities
$7.38M
Debt
$290,000
Equity
$321.07M
Working capital
$286.5M
Debt to equity
0
Current ratio
40.33
Quick ratio
38.74
Net debt/EBITDA
0.7
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-15.7%
Return on equity
-16%
Return on invested capital
-22.3%
Return on capital employed
-15.2%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
TRML stock price
How has the Tourmaline Bio stock price performed over time
Intraday
-5.33%
1 week
-15.48%
1 month
-19.73%
1 year
29.16%
YTD
-13.22%
QTD
-11.63%
Financial performance
How have Tourmaline Bio's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$59.82M
Net income
-$48.85M
Gross margin
N/A
Net margin
N/A
Tourmaline Bio's net income has decreased by 43% QoQ
Tourmaline Bio's operating income has decreased by 42% from the previous quarter
Growth
What is Tourmaline Bio's growth rate over time
Valuation
What is Tourmaline Bio stock price valuation
P/E
N/A
P/B
1.81
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
TRML's EPS has surged by 99% year-on-year and by 92% since the previous quarter
TRML's equity has soared by 125% year-on-year but it is down by 5% since the previous quarter
Efficiency
How efficient is Tourmaline Bio business performance
The company's return on assets fell by 22% QoQ
Tourmaline Bio's ROE has decreased by 21% from the previous quarter
TRML's return on invested capital is down by 8% since the previous quarter
Dividends
What is TRML's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for TRML.
Financial health
How did Tourmaline Bio financials performed over time
The total assets has soared by 117% YoY but it has contracted by 4.7% from the previous quarter
Tourmaline Bio's current ratio has surged by 116% YoY but it has decreased by 14% QoQ
The company's debt is 100% lower than its equity
TRML's equity has soared by 125% year-on-year but it is down by 5% since the previous quarter
The company's debt has shrunk by 54% YoY and by 13% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.